| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1020657355 |
| P356 | DOI | 10.1023/A:1006456717846 |
| P698 | PubMed publication ID | 11291833 |
| P2093 | author name string | K Itoh | |
| H Fujii | |||
| Y Sasaki | |||
| T Igarashi | |||
| H Minami | |||
| T Ohtsu | |||
| T Miya | |||
| T Goya | |||
| P2860 | cites work | Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function | Q33477777 |
| The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide | Q33503906 | ||
| A formula to estimate the approximate surface area if height and weight be known. 1916. | Q34437560 | ||
| Clinical pharmacokinetics-pharmacodynamics of anticancer drugs | Q38649105 | ||
| Descriptive epidemiology of body weight and weight change in U.S. adults | Q40841346 | ||
| Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative | Q41123160 | ||
| Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. | Q43706400 | ||
| Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity | Q44317117 | ||
| A population pharmacokinetic model for docetaxel (Taxotere): model building and validation | Q46171352 | ||
| Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients | Q47201592 | ||
| Estimation of human body surface area from height and weight | Q47387886 | ||
| A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. | Q49164024 | ||
| Pharmacokinetics of sufentanil in obese patients | Q51701894 | ||
| A pharmacokinetic analysis program (multi) for microcomputer | Q52732710 | ||
| Pharmacokinetic study of mitomycin C with emphasis on the influence of aging. | Q55310922 | ||
| Etoposide pharmacokinetics in patients with normal and abnormal organ function | Q57223635 | ||
| Doxorubicin clearance in the obese | Q68489640 | ||
| Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse | Q68715234 | ||
| Nonlinear pharmacokinetics of CPT-11 in rats | Q68715236 | ||
| Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution | Q69361463 | ||
| Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia | Q70209174 | ||
| Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry | Q71730035 | ||
| Prediction of carboplatin clearance from standard morphological and biological patient characteristics | Q72241637 | ||
| The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function | Q72280919 | ||
| Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation | Q74784073 | ||
| Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests | Q74824093 | ||
| P433 | issue | 1 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 61-67 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. | |
| P478 | volume | 19 |
| Q36154581 | Body Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review |
| Q36245977 | Body mass index influences the response to infliximab in ankylosing spondylitis |
| Q35039124 | Colorectal cancer in the elderly: is palliative chemotherapy of value? |
| Q38757733 | GSK-3 inhibition overcomes chemoresistance in human breast cancer |
| Q26775949 | Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer |
| Q43188323 | Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma |
| Q37336474 | Part II: Liver function in oncology: towards safer chemotherapy use. |
| Q35579412 | Pharmacology of Anticancer Drugs in the Elderly Population |
| Q40513457 | Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience |
| Q36975047 | Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms |
Search more.